IMMUTEP ADR WKN: A2H8YL ISIN: US45257L1089 Kürzel: IMMP Forum: Aktien Thema: Hauptdiskussion

WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321 https://seekingalpha.com/pr/17787266?source=ansh $IMMP, $WXXWY

Immutep’s study has reportedly recorded that 47% of 1st line non-small cell lung cancer patients and 33% of 2nd line head and neck squamous cell carcinoma patients, reported encouraging responses. https://smallcaps.com.au/immutep-reports-positive-data-ongoing-trial-cancer-drug-efti/

http://stocktwits.com/tkathlina/message/195448127

Morgen wird es nochmal interessant

Dann im März Daten der größeren Studie.

Ich denke krebskongress in Berlin ist hier das nächste Ziel.

Immutep Activities Report    January 29, 2020 08:00 ET | Source: Immutep Limited First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020 More mature data expected from TACTI-002 in February 2020 Sufficiently funded to deliver key upcoming catalysts http://www.globenewswire.com/news-release/2020/01/29/1976732/0/en/Immutep-Activities-Report.html

http://stocktwits.com/tripleface/message/191113215

Zu viert! 😉 Da ist ordentlich was in der Pipeline bei Immutep!

http://stocktwits.com/tripleface/message/190167735

Jupp q1 2020 ist interessant hier 😀

Oha jetzt sind wir schon zu dritt. :) es geht Berg auf

https://themarketherald.com.au/immutep-asximm-expands-part-c-of-tacti-002-study-due-to-positive-data-2020-01/

https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/immutep-limiteds-asximm-shift-from-loss-to-profit/

http://stocktwits.com/jeremy80/message/189609071

Near-Term Upside In LAG-3 Immunotherapy - Buy Immutep Summary LAG-3 - An emerging field in immunotherapy drug development. Immutep's 227 patient study in Metastatic Breast Cancer due to report in March 2020. Downside protection with Big Pharma relationships and multiple clinical trials currently underway. Undervalued stock with than US$100 million market capitalisation. Immutep (ASX:IMM, IMMP) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism. Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the late 1990s that a soluble protein called LAG-3 could activate dendritic cells in the vicinity of tumour https://seekingalpha.com/article/4313526?source=ansh $IMMP